Detalles de la búsqueda
1.
Efficacy of Single-Agent Chemotherapy in Endocrine Therapy-Refractory Metastatic Invasive Lobular Carcinoma.
Oncologist
; 29(3): 213-218, 2024 Mar 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38070191
2.
Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment.
Breast Cancer Res
; 25(1): 62, 2023 06 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37280713
3.
Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2- metastatic breast cancer patients compared to endocrine therapy alone in the second-line setting: A large institutional study.
Int J Cancer
; 150(12): 2025-2037, 2022 06 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35133007
4.
Effects of systemic therapy and local therapy on outcomes of 873 breast cancer patients with metastatic breast cancer to brain: MD Anderson Cancer Center experience.
Int J Cancer
; 148(4): 961-970, 2021 02 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32748402
5.
A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores.
Breast Cancer Res Treat
; 189(2): 455-461, 2021 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-34131830
6.
Factors associated with MRI detection of occult lesions in newly diagnosed breast cancers.
J Surg Oncol
; 121(4): 589-598, 2020 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-31984517
7.
Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2-Targeted Therapy.
Oncologist
; 24(3): 313-318, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30139836
8.
Lapatinib activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab, pertuzumab, and/or ado-trastuzumab emtansine (T-DM1).
Breast Cancer Res Treat
; 176(1): 227-234, 2019 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-30977027
9.
Clinical findings and outcomes of MRI staging of breast cancer in a diverse population.
Breast Cancer Res Treat
; 174(2): 315-324, 2019 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-30542816
10.
Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study.
Invest New Drugs
; 37(2): 345-351, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30610588
11.
Genetic Counseling Referral Rates in Long-Term Survivors of Triple-Negative Breast Cancer.
J Natl Compr Canc Netw
; 16(5): 518-524, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29752326
12.
Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay.
Cancer
; 123(13): 2422-2431, 2017 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28199747
13.
Mammographic breast density is associated with the development of contralateral breast cancer.
Cancer
; 123(11): 1935-1940, 2017 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28135395
14.
Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy.
Br J Cancer
; 116(4): 509-514, 2017 Feb 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-28081544
15.
Breast Cancer Brain Metastasis: A Comprehensive Review.
JCO Oncol Pract
; : OP2300794, 2024 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38748968
16.
Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2-negative stage II-III breast cancer.
Oncotarget
; 15: 238-247, 2024 Mar 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-38502947
17.
Bone-Targeted Therapy Regimen and Skeletal-Related Events in Patients Surviving Longer Than 2 Years With Metastatic Breast Cancer and Bone Metastasis.
Clin Breast Cancer
; 23(8): e515-e522, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37735019
18.
Survival Outcomes in Patients With Hormone Receptor-Positive Metastatic Breast Cancer With Low or No ERBB2 Expression Treated With Targeted Therapies Plus Endocrine Therapy.
JAMA Netw Open
; 6(5): e2313017, 2023 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37166793
19.
Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment.
Res Sq
; 2023 Feb 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-36824840
20.
Absence of lobular carcinoma in situ is a poor prognostic marker in invasive lobular carcinoma.
Eur J Cancer
; 191: 113250, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37573674